| Stat5 is indispensable for the maintenance of bcr/abl‐positive leukaemia A Hoelbl, C Schuster, B Kovacic, B Zhu, M Wickre, MA Hoelzl, S Fajmann, ... EMBO molecular medicine 2 (3), 98-110, 2010 | 310 | 2010 |
| Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia F Grebien, M Vedadi, M Getlik, R Giambruno, A Grover, R Avellino, ... Nature chemical biology 11 (8), 571-578, 2015 | 302 | 2015 |
| CD14 is a coreceptor of Toll-like receptors 7 and 9 CL Baumann, IM Aspalter, O Sharif, A Pichlmair, S Blüml, F Grebien, ... Journal of Experimental Medicine 207 (12), 2689-2701, 2010 | 279 | 2010 |
| JAK-STAT signaling in cancer: From cytokines to non-coding genome J Pencik, HTT Pham, J Schmoellerl, T Javaheri, M Schlederer, Z Culig, ... Cytokine 87, 26-36, 2016 | 241 | 2016 |
| Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation P Filippakopoulos, M Kofler, O Hantschel, GD Gish, F Grebien, E Salah, ... Cell 134 (5), 793-803, 2008 | 238 | 2008 |
| BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia O Hantschel, W Warsch, E Eckelhart, I Kaupe, F Grebien, KU Wagner, ... Nature chemical biology 8 (3), 285-293, 2012 | 237 | 2012 |
| A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain J Wojcik, O Hantschel, F Grebien, I Kaupe, KL Bennett, J Barkinge, ... Nature structural & molecular biology 17 (4), 519-527, 2010 | 206 | 2010 |
| STAT3 regulated ARF expression suppresses prostate cancer metastasis J Pencik, M Schlederer, W Gruber, C Unger, SM Walker, A Chalaris, ... Nature communications 6 (1), 7736, 2015 | 185 | 2015 |
| Evidence for a size-sensing mechanism in animal cells H Dolznig, F Grebien, T Sauer, H Beug, EW Müllner Nature cell biology 6 (9), 899-905, 2004 | 185 | 2004 |
| Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis F Grebien, O Hantschel, J Wojcik, I Kaupe, B Kovacic, AM Wyrzucki, ... Cell 147 (2), 306-319, 2011 | 175 | 2011 |
| Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2 F Grebien, MA Kerenyi, B Kovacic, T Kolbe, V Becker, H Dolznig, K Pfeffer, ... Blood, The Journal of the American Society of Hematology 111 (9), 4511-4522, 2008 | 169 | 2008 |
| Pharmacologic inhibition of STAT5 in acute myeloid leukemia B Wingelhofer, B Maurer, EC Heyes, AA Cumaraswamy, A Berger-Becvar, ... Leukemia 32 (5), 1135-1146, 2018 | 151 | 2018 |
| HBO1 is required for the maintenance of leukaemia stem cells L MacPherson, J Anokye, MM Yeung, EYN Lam, YC Chan, CF Weng, ... Nature 577 (7789), 266-270, 2020 | 143 | 2020 |
| Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site E Hadzijusufovic, K Albrecht-Schgoer, K Huber, G Hoermann, F Grebien, ... Leukemia 31 (11), 2388-2397, 2017 | 142 | 2017 |
| Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1 MA Kerenyi, F Grebien, H Gehart, M Schifrer, M Artaker, B Kovacic, ... Blood, The Journal of the American Society of Hematology 112 (9), 3878-3888, 2008 | 134 | 2008 |
| Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML GE Winter, U Rix, SM Carlson, KV Gleixner, F Grebien, M Gridling, ... Nature chemical biology 8 (11), 905-912, 2012 | 120 | 2012 |
| The growing arsenal of ATP-competitive and allosteric inhibitors of BCR–ABL O Hantschel, F Grebien, G Superti-Furga Cancer research 72 (19), 4890-4895, 2012 | 107 | 2012 |
| STAT5BN642H is a driver mutation for T cell neoplasia HTT Pham, B Maurer, M Prchal-Murphy, R Grausenburger, ... The Journal of clinical investigation 128 (1), 387-401, 2018 | 96 | 2018 |
| Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR H Dolznig, F Grebien, EM Deiner, K Stangl, A Kolbus, B Habermann, ... Oncogene 25 (20), 2890-2900, 2006 | 84 | 2006 |
| Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression S Terlecki-Zaniewicz, T Humer, T Eder, J Schmoellerl, E Heyes, ... Nature structural & molecular biology 28 (2), 190-201, 2021 | 81 | 2021 |
Giulio Superti-FurgaScientific Director, CeMM Research Center for Molecular Medicine of the Austrian Academy ofVerified email at cemm.oeaw.ac.at
